UPEXI, INC. - 10-Q Filing Summary
Business Context and Reporting Period
Company: UPEXI, INC. (UPXI)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended March 31, 2025
Business Overview: Upexi operates in the branded consumer products sector, focusing on health, wellness, and pet products. The company has recently executed a strategic shift away from its "recommerce" business lines (E-Core, VitaMedica, Interactive Offers), which have been classified as discontinued operations. Operations are consolidated in Florida, with a focus on direct-to-consumer, wholesale, and Amazon sales.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2025 |
Nine Months Ended March 31, 2025 |
As of March 31, 2025 |
|---|---|---|---|
| Revenue | $3,160,480 | $11,522,487 | - |
| Gross Profit | $1,559,106 | $7,463,280 | - |
| Gross Margin | 49.3% | 64.8% | - |
| Net Loss (Continuing Ops) | $(3,831,660) | $(6,758,547) | - |
| Net Loss (Total) | $(3,831,660) | $(6,758,547) | - |
| Cash and Equivalents | - | - | $230,392 |
| Total Assets | - | - | $15,067,314 |
| Total Liabilities | - | - | $13,216,604 |
| Working Capital | - | - | $(6,828,044) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 39% ($2.06M) for the quarter and 45% ($9.44M) for the nine-month period compared to the prior year. Management attributes approximately $8.3M of the nine-month decline to the strategic exit from the recommerce business (E-Core, VitaMedica).
- Margin Expansion: Despite lower revenue, gross profit margins improved significantly. For the nine months ended March 31, 2025, the gross margin was 64.8% compared to 54% in the prior year period, driven by the shift to higher-margin branded products.
- Expense Reduction: Distribution costs dropped 52% ($1.07M) for the quarter and 44% ($2.97M) for the nine months, aligning with the reduction in recommerce volume. Sales and marketing expenses also decreased.
- Increased G&A: General and administrative expenses increased 46% ($828k) for the quarter. This was driven by a full reserve on accounts receivable from Amazon (funds held >90 days) and elevated legal/auditing costs related to restructuring.
- Asset Sales: The company generated significant investing cash flow ($5.76M) from the sale of its Florida building ($4.0M) and the collection of the E-Core purchase price ($2.0M).
Guidance, Outlook, and Risks
- Strategic Focus: Management is focused on the development, production, and distribution of branded products. Restructuring of operations is expected to be complete as of May 1, 2025, with G&A expenses expected to normalize.
- Liquidity: As of March 31, 2025, cash was $230,392. The company reported a negative working capital of $6.8M. However, management estimates sufficient working capital for the next 12 months following a subsequent private placement.
- Subsequent Financing: On April 24, 2025, the company closed a private placement raising approximately $92.6M net from the sale of common stock and pre-funded warrants.
- Internal Controls: The company disclosed material weaknesses in internal controls, specifically regarding inadequate segregation of duties and lack of multiple levels of supervision. Remediation is planned for the end of the 2025 fiscal year.
- Legal Proceedings: The company is involved in active arbitration with Get Fit Fast Supplements, LLC regarding the acquisition of Cygnet Online, LLC, involving claims of breach of contract and fraud.
- Regulatory Risk: Uncertainty remains regarding federal and state regulation of hemp-derived cannabinoids, which could impact market access.
Investor Verification Checklist
- Cash Position vs. Debt: Verify the impact of the $92.6M subsequent financing on the current debt load (approx. $7.3M total notes payable) and working capital deficit.
- Amazon Receivables: Confirm the status of the Amazon receivables reserved in the period; management noted funds held for over 90 days with full reserves taken.
- Related Party Transactions: Review the lease agreement with the CEO (Allan Marshall) for the Odessa, FL facility and the purchase of Series A preferred stock by the CEO.
- Inventory Valuation: Assess the $499k inventory write-off and the $803k inventory reserve, particularly regarding slow-moving recommerce products.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting controls to ensure future reporting reliability.